In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Esperion Therapeutics Inc. (NASDAQ:ESPR) reported that Alta Partners Viii, L.p. has picked up 1,431,204 of common stock as of 2017-03-27.

The acquisition brings the aggregate amount owned by Alta Partners Viii, L.p. to a total of 1,431,204 representing a 6.3% stake in the company

For those not familiar with the company, Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

A glance at Esperion Therapeutics Inc. (NASDAQ:ESPR)’s key stats reveals a current market capitalization of 832.02 Million based on 22.56 Million shares outstanding and a price at last close of $38.27 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-03-21, Omenn picked up 1,000 at a purchase price of $42.46. This brings their total holding to 1,000 as of the date of the filing.

On the sell side, the most recent transaction saw Janney unload 700 shares at a sale price of $48.19. This brings their total holding to 1,359,967.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Esperion Therapeutics Inc. (NASDAQ:ESPR) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.